Kohzo Nagata

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7223831/publications.pdf

Version: 2024-02-01

		186265	223800
52	2,135	28	46
papers	citations	h-index	g-index

52	52	52	2852
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pharmacological inhibition of the lipid phosphatase PTEN ameliorates heart damage and adipose tissue inflammation in stressed rats with metabolic syndrome. Physiological Reports, 2022, 10, e15165.	1.7	2
2	The prebiotic fiber inulin ameliorates cardiac, adipose tissue, and hepatic pathology, but exacerbates hypertriglyceridemia in rats with metabolic syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H281-H295.	3.2	5
3	Surgical ablation of whitened interscapular brown fat ameliorates cardiac pathology in saltâ€loaded metabolic syndrome rats. Annals of the New York Academy of Sciences, 2021, 1492, 11-26.	3.8	1
4	Alleviation of salt-induced exacerbation of cardiac, renal, and visceral fat pathology in rats with metabolic syndrome by surgical removal of subcutaneous fat. Nutrition and Diabetes, 2020, 10, 28.	3.2	4
5	Effects of ramelteon on cardiac injury and adipose tissue pathology in rats with metabolic syndrome. Annals of the New York Academy of Sciences, 2018, 1421, 73-87.	3.8	9
6	Anti-inflammatory effects of heat-killed Lactobacillus plantarum L-137 on cardiac and adipose tissue in rats with metabolic syndrome. Scientific Reports, 2018, 8, 8156.	3.3	38
7	Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome. International Journal of Cardiology, 2017, 240, 332-338.	1.7	36
8	Effects of mTOR inhibition on cardiac and adipose tissue pathology and glucose metabolism in rats with metabolic syndrome. Pharmacology Research and Perspectives, 2017, 5, e00331.	2.4	14
9	Effects of various types of anesthesia on hemodynamics, cardiac function, and glucose and lipid metabolism in rats. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H1360-H1366.	3.2	57
10	LamininÎ±2-secreting fibroblasts enhance the therapeutic effect of skeletal myoblast sheets. European Journal of Cardio-thoracic Surgery, 2016, 51, ezw296.	1.4	7
11	Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. Hypertension Research, 2015, 38, 39-47.	2.7	16
12	Blockade of glucocorticoid receptors with RU486 attenuates cardiac damage and adipose tissue inflammation in a rat model of metabolic syndrome. Hypertension Research, 2015, 38, 741-750.	2.7	27
13	Restraint stress exacerbates cardiac and adipose tissue pathology via Î²-adrenergic signaling in rats with metabolic syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H1275-H1286.	3.2	32
14	Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome. International Journal of Cardiology, 2015, 179, 360-369.	1.7	39
15	Roles of oxidative stress and the mineralocorticoid receptor in cardiac pathology in a rat model of metabolic syndrome. Nagoya Journal of Medical Science, 2015, 77, 275-89.	0.3	6
16	Generation of Rat-Induced Pluripotent Stem Cells from a New Model of Metabolic Syndrome. PLoS ONE, 2014, 9, e104462.	2.5	10
17	Effects of salt status and blockade of mineralocorticoid receptors on aldosterone-induced cardiac injury. Hypertension Research, 2014, 37, 125-133.	2.7	18
18	Dietary Salt Restriction Improves Cardiac and Adipose Tissue Pathology Independently of Obesity in a Rat Model of Metabolic Syndrome. Journal of the American Heart Association, 2014, 3, e001312.	3.7	36

#	Article	IF	Citations
19	Glucocorticoids activate cardiac mineralocorticoid receptors in adrenalectomized Dahl salt-sensitive rats. Nagoya Journal of Medical Science, 2014, 76, 59-72.	0.3	10
20	Premature cardiac senescence in DahlS.Z-Lepr(fa)/Lepr(fa) rats as a new animal model of metabolic syndrome. Nagoya Journal of Medical Science, 2014, 76, 35-49.	0.3	10
21	Calorie Restriction Attenuates Cardiac Remodeling and Diastolic Dysfunction in a Rat Model of Metabolic Syndrome. Hypertension, 2013, 62, 957-965.	2.7	66
22	Effects of Aged Garlic Extract on Left Ventricular Diastolic Function and Fibrosis in a Rat Hypertension Model. Experimental Animals, 2013, 62, 305-310.	1.1	13
23	Glucocorticoid-induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism. Nagoya Journal of Medical Science, 2013, 75, 81-92.	0.3	18
24	Effects of Estrogen on Cardiovascular Injury in Ovariectomized Female DahlS.Z- Lepr ^{fa} /Lepr ^{fa} Rats as a New Animal Model of Metabolic Syndrome. Hypertension, 2012, 59, 694-704.	2.7	32
25	Comparison of the effects of cilnidipine and amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. Journal of Hypertension, 2012, 30, 1845-1855.	0.5	23
26	Cardiac remodeling and diastolic dysfunction in DahlS.Z-Leprfa/Leprfa rats: a new animal model of metabolic syndrome. Hypertension Research, 2012, 35, 186-193.	2.7	56
27	Angiotensin-Converting Enzyme Inhibition Promotes Coronary Angiogenesis in the Failing Heart of Dahl Salt-Sensitive Hypertensive Rats. Journal of Cardiac Failure, 2011, 17, 1041-1050.	1.7	32
28	Mechanism underlying the efficacy of combination therapy with losartan and hydrochlorothiazide in rats with salt-sensitive hypertension. Hypertension Research, 2011, 34, 809-816.	2.7	19
29	Cardioprotective mechanisms of lifestyle modifications and pharmacotherapies on cardiac remodeling and dysfunction in hypertensive heart disease: an overview. Nagoya Journal of Medical Science, 2011, 73, 91-105.	0.3	4
30	Ca2+ channel blocker benidipine promotes coronary angiogenesis and reduces both left-ventricular diastolic stiffness and mortality in hypertensive rats. Journal of Hypertension, 2010, 28, 1515-1526.	0.5	15
31	Exercise Training Alters Left Ventricular Geometry and Attenuates Heart Failure in Dahl Salt-Sensitive Hypertensive Rats. Hypertension, 2009, 53, 701-707.	2.7	72
32	Long-term administration of nifedipine attenuates cardiac remodeling and diastolic heart failure in hypertensive rats. European Journal of Pharmacology, 2009, 615, 163-170.	3.5	34
33	Mechanism of Diastolic Stiffening of the Failing Myocardium and Its Prevention by Angiotensin Receptor and Calcium Channel Blockers. Journal of Cardiovascular Pharmacology, 2009, 54, 47-56.	1.9	19
34	Mineralocorticoid antagonism and cardiac hypertrophy. Current Hypertension Reports, 2008, 10, 216-221.	3.5	13
35	Xanthine Oxidase Inhibition Improves Left Ventricular Dysfunction in Dilated Cardiomyopathic Hamsters. Journal of Cardiac Failure, 2008, 14, 238-244.	1.7	29
36	Superoxide-Dependent Cathepsin Activation Is Associated with Hypertensive Myocardial Remodeling and Represents a Target for Angiotensin II Type 1 Receptor Blocker Treatment. American Journal of Pathology, 2008, 173, 358-369.	3.8	55

#	Article	IF	Citations
37	Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. Journal of Hypertension, 2008, 26, 1669-1676.	0.5	53
38	Aldosterone modulates If current through gene expression in cultured neonatal rat ventricular myocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H2710-H2718.	3.2	32
39	Attenuation of cardiac dysfunction by a PPAR-Î± agonist is associated with down-regulation of redox-regulated transcription factors. Journal of Molecular and Cellular Cardiology, 2006, 41, 318-329.	1.9	106
40	Elastolytic Cathepsin Induction/Activation System Exists in Myocardium and Is Upregulated in Hypertensive Heart Failure. Hypertension, 2006, 48, 979-987.	2.7	87
41	Pitavastatin Improves Cardiac Function and Survival in Association With Suppression of the Myocardial Endothelin System in a Rat Model of Hypertensive Heart Failure. Journal of Cardiovascular Pharmacology, 2006, 47, 770-779.	1.9	48
42	ATTENUATION OF VENTRICULAR HYPERTROPHY AND FIBROSIS IN RATS BY PITAVASTATIN: POTENTIAL ROLE OF THE RhoA?EXTRACELLULAR SIGNAL-REGULATED KINASE?SERUM RESPONSE FACTOR SIGNALLING PATHWAY. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 1164-1171.	1.9	30
43	Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovascular Research, 2006, 69, 726-735.	3.8	75
44	Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Failure in Low-Aldosterone Hypertensive Rats. Hypertension, 2006, 47, 656-664.	2.7	207
45	Mineralocorticoid Receptor Antagonism Ameliorates Left Ventricular Diastolic Dysfunction and Myocardial Fibrosis in Mildly Symptomatic Patients With Idiopathic Dilated Cardiomyopathy. Circulation, 2005, 112, 2940-2945.	1.6	236
46	Nicorandil Promotes Myocardial Capillary and Arteriolar Growth in the Failing Heart of Dahl Salt-Sensitive Hypertensive Rats. Hypertension, 2005, 46, 719-724.	2.7	46
47	Myocardial velocity gradient as a noninvasively determined index of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2003, 42, 278-285.	2.8	62
48	Nicorandil inhibits oxidative stress-induced apoptosis in cardiac myocytes through activation of mitochondrial ATP-sensitive potassium channels and a nitrate-like effect. Journal of Molecular and Cellular Cardiology, 2003, 35, 1505-1512.	1.9	52
49	AT 1 Receptor Blockade Reduces Cardiac Calcineurin Activity in Hypertensive Rats. Hypertension, 2002, 40, 168-174.	2.7	104
50	Effects of FK506 and rapamycin on formation of the neural tube in chick embryos. Animal Science Journal, 2002, 73, 229-234.	1.4	1
51	Reduced Myocardial Sarcoplasmic Reticulum Ca ²⁺ -ATPase mRNA Expression and Biphasic Force-Frequency Relations in Patients With Hypertrophic Cardiomyopathy. Circulation, 2001, 104, 658-663.	1.6	84
52	Differential effects of dobutamine and a phosphodiesterase inhibitor on early diastolic filling in patients with congestive heart failure. Journal of the American College of Cardiology, 1995, 25, 295-304.	2.8	35